Preclinical development of plant-based oral immune modulatory therapy for haemophilia B. [PDF]
Srinivasan A +6 more
europepmc +1 more source
ABSTRACT Managing thrombosis in patients with bleeding disorders requires careful assessment of thromboembolic and bleeding risks, tailoring antithrombotic treatment in terms of type, dose, and duration, and considering the need for replacement therapy based on individual factor levels and bleeding history.
Synnøve Gjelsten Mortensen +4 more
wiley +1 more source
ABSTRACT A 7.6‐year‐old boy with hTTP had fever‐induced hemorrhagic rash, MAHA, cerebral infarction, and renal impairment. After plasma therapy, symptoms were partially relieved; 9‐year follow‐up showed regular plasma transfusion was needed, with CKD Stage 3.
Dai Xiaomei +5 more
wiley +1 more source
Ddavp treatment in children with haemophilia b [PDF]
Kavakli, K +3 more
openaire +2 more sources
Real-World Unmet Needs of Patients With Haemophilia A and Haemophilia B With or Without Inhibitors: End-of-Study Results From the explorer6 Non-Interventional Study. [PDF]
Wheeler AP +14 more
europepmc +1 more source
ABSTRACT Spinal epidural abscess (SEA) is an easily misdiagnosed disease. We report a case of primary SEA (PSEA) that was misdiagnosed as spinal epidural hematoma (SEH) and analyze the reasons. The misdiagnosis was confirmed intraoperatively. Comprehensive analysis is crucial for the diagnosis of PSEA and its differential diagnosis from SEH.
Sheng‐Wei Meng +2 more
wiley +1 more source
Comparing Real-World Outcomes of Prophylaxis with Extended Half-life Factor IX (rIX-FP vs. rFIXFc and N9-GP) for Haemophilia B: An Analysis of Medical Chart Data from Germany. [PDF]
Olivieri M +8 more
europepmc +1 more source
High adherence to prophylaxis regimens in haemophilia B patients receiving rIX-FP: Evidence from clinical trials and real-world practice. [PDF]
Mancuso ME +7 more
europepmc +1 more source
Precision medicine offers the opportunity to improve the benefit–risk profile of new therapies by prospectively identifying patients most likely to respond or least likely to experience harm; however, its systematic integration into drug development remains inconsistent outside oncology.
Ingrid Holst‐Laubjerg +1 more
wiley +1 more source
Real-world usage and effectiveness of recombinant factor IX Fc in haemophilia B from the B-SURE study in France. [PDF]
Chambost H +11 more
europepmc +1 more source

